Merck & Co. Inc. (MRK)
-NYSE 47.58 
0.17(0.36%) Jun 19, 4:00PM EDT|After Hours
:
47.65 0.07 (0.15%) Jun 19, 7:30PM EDT
| Prev Close: | 47.75 |
|---|
| Open: | 47.69 |
|---|
| Bid: | 47.58 x 100 |
|---|
| Ask: | 47.70 x 500 |
|---|
| 1y Target Est: | 52.33 |
|---|
| Beta: | 0.37 |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | 47.45 - 48.17 |
|---|
| 52wk Range: | 39.29 - 50.16 |
|---|
| Volume: | 18,000,478 |
|---|
| Avg Vol (3m): | 18,541,900 |
|---|
| Market Cap: | 143.67B |
|---|
| P/E (ttm): | 24.28 |
|---|
| EPS (ttm): | 1.96 |
|---|
| Div & Yield: | 1.72 (3.60%) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- HPV vaccine cut infection by half in teen girlsAP(Wed, Jun 19)
- An AstraZeneca And Bristol-Myers Diabetes Trial Is A Dudat Forbes(Wed, Jun 19)
- Cancer-Causing Sex Virus Cut in Teen Girls by Vaccinesat Bloomberg(Wed, Jun 19)
- Cervical cancer vaccines cut rates of HPV infections -U.S.at Reuters(Wed, Jun 19)
- Don’t Invest in Biotech IPOs Until You Read Thisat Motley Fool(Wed, Jun 19)
- No More Secrets: Medtronic Shows How Open Science Might Work In The Real Worldat Forbes(Wed, Jun 19)
- This Blockbuster Biologic May Face a Steep Cliffat Motley Fool(Wed, Jun 19)
- Bond Yields Are Rising -- Do Your Stocks Measure Up?StreetAuthority Network(Wed, Jun 19)
- Europe Fines Drug Companies for Delaying Genericsat New York Times(Wed, Jun 19)
- AstraZeneca, Bristol diabetes drug disappoints in key testat Reuters(Wed, Jun 19)
- The Dow's Triple-Digit Gains Left These Stocks Behindat Motley Fool(Tue, Jun 18)
- GE Stock Leads Dow’s 138-Point Surgeat Motley Fool(Tue, Jun 18)
- Merck Stock Lags Solid Gains on Wall Streetat Motley Fool(Tue, Jun 18)
- Top Treatments for High Cholesterolat Motley Fool(Tue, Jun 18)
- Largest option buying in equities so faroptionMONSTER(Tue, Jun 18)
Press Releases
- Litigation Settlements, Data Compliance Reviews, and Clinical Trials Pave Way for Solid Footing in Healthcare - Research Report on Pfizer, Merck, Bristol-Myers Squibb, Keryx and Pacira PharmaceuticalsPR Newswire(Mon, Jun 17)
- Merck Welcomes Independent Review of the Safety Profile of JANUVIA® (sitagliptin) and Other Diabetes MedicinesBusiness Wire(Wed, Jun 12)
- Merck Announces Presentation of Interim Data from Study Evaluating Lambrolizumab, an Investigational Anti-PD-1 Antibody, in Patients with Advanced Melanoma at ASCO 2013Business Wire(Sun, Jun 2)
Key Statistics
| Forward P/E (1 yr): | 12.72 |
|---|
| P/S (ttm): | 3.12 |
|---|
| Ex-Dividend Date: | 13-Jun-13 |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | 3.50 |
|---|
| Quarterly EPS Est
(Jun-13)
: | 0.84 |
|---|
| Mean Recommendation*: | 2.2 |
|---|
| PEG Ratio (5 yr expected): | 4.47 |
|---|
Business Summary
Merck & Co., Inc. provides various health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products worldwide.
View More